Earn Up to 2 Hours of CME!

Zoom Platform

Pre-Registration is required.

Registration Fee: $25.00

Program Description

Bruton’s tyrosine kinase inhibitors (BTKi) have transformed how B-cell malignancies are managed. Understanding their mechanisms—whether covalent or non-covalent—as well as recognizing the similarities and differences in safety profiles and handling specific adverse events, allows clinicians to use BTK inhibitors confidently and efficiently in everyday practice. Expert-led education is essential for clinicians to formulate personalized treatment strategies that incorporate different types of BTK inhibitors for suitable patient groups affected by B-cell malignancies.